Achieve Life Sciences to Host Meetings During the J.P. Morgan Healthcare Conference Week

To date, Achieve has successfully completed two Phase 3 clinical trials of cytisinicline in more than 1,600 subjects who smoke combustible cigarettes and one Phase 2 clinical trial for adults who vape nicotine e-cigarettes and desire to quit. Achieve expects to submit a New Drug Application (NDA) for cytisinicline as an aid to smoking cessation in the second quarter of 2025. Additionally, it expects to commence a single Phase 3 clinical trial of cytisinicline for nicotine e-cigarette or vaping cessation in the third quarter of 2025. Read More

Achieve Life Sciences to Host Meetings During the J.P. Morgan Healthcare Conference Week

Achieve Life Sciences to Host Meetings During the J.P. Morgan Healthcare Conference Week

Achieve Life Sciences to Host Meetings During the J.P. Morgan Healthcare Conference Week

Achieve Life Sciences to Host Meetings During the J.P. Morgan Healthcare Conference Week

Achieve Life Sciences to Host Meetings During the J.P. Morgan Healthcare Conference Week